With regard to the molecular mechanism of STEAP2 in prostate cancers, Gonen-Korkmaz et al. (2014) overexpressed STEAP2, in AR-negative DU145 prostate cancer cells, and showed an NFκB-mediated downregulation of STEAP2 expression following treatment with tumor necrosis factor-α (TNF-α). This evidence concerns the gene STEAP2 and prostate carcinoma.